更新于：2024-11-04
Tinidazole
替硝唑
更新于：2024-11-04
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (1994-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构
分子式C8H13N3O4S |
InChIKeyHJLSLZFTEKNLFI-UHFFFAOYSA-N |
CAS号19387-91-8 |
关联
45
项与 替硝唑 相关的临床试验Oral Tinidazole Treatment of Refractory Trichomonas Vaginitis
Porphyromonas Gingivalis Elimination From Oral Improves Esophageal Cancer Patients Survival After Radical Operation
Fasted-state in vivo bioequivalence study of Tinidazole 500 mg tablet
100 项与 替硝唑 相关的临床结果
登录后查看更多信息
100 项与 替硝唑 相关的转化医学
登录后查看更多信息
100 项与 替硝唑 相关的专利（医药）
登录后查看更多信息
1,516
项与 替硝唑 相关的文献（医药）2024-11-01ULTRASONICS SONOCHEMISTRY
Ultrasonically assisted fabrication of electrochemical platform for tinidazole detection
Article
作者: Cui, Wenyu ; Zhang, Chaojun ; Yang, Wein-Duo ; Liu, Rijia ; Liu, Rui ; Sun, Yuan
Based on sonochemistry, green synthesis methods play an important role in the development of nanomaterials. In this work, a novel chitosan modified MnMoO4/g-C3N4 (MnMoO4/g-C3N4/CHIT) was developed using ultrasonic cell disruptor (500 W, 30 kHz) for ultra-sensitive electrochemical detection of tinidazole (TNZ) in the environment. The morphology and surface properties of the synthesized MnMoO4/g-C3N4/CHIT electrode were characterized using X-ray diffraction (XRD), fourier transform infrared spectroscopy (FT-IR), scanning electron microscope (SEM) and transmission electron microscope (TEM). Cyclic voltammetry (CV) and differential pulse voltammetry (DPV) techniques were utilized to assess the electrochemical performance of TNZ. The results indicate that the electrochemical detection performance of TNZ is highly efficient, with a detection limit (LOD) of 3.78 nM, sensitivity of 1.320 µA·µM-1·cm-2, and a detection range of 0.1-200 μM. Additionally, the prepared electrode exhibits excellent selectivity, desirable anti-interference capability, and decent stability. MnMoO4/g-C3N4/CHIT can be successfully employed to detect TNZ in both the Songhua River and tap water, achieving good recovery rates within the range of 93.0 % to 106.6 %. Consequently, MnMoO4/g-C3N4/CHIT's simple synthesis might provide a new electrode for the sensitive, repeatable, and selective measurement of TNZ in real-time applications. Using the MnMoO4/g-C3N4/CHIT electrode can effectively monitor and detect the concentration of TNZ in environmental water, guiding the sewage treatment process and reducing the pollution level of antibiotics in the water environment.
2024-11-01ADVANCED MATERIALS
Ultrasound‐Activated Probiotics Vesicles Coating for Titanium Implant Infections Through Bacterial Cuproptosis‐Like Death and Immunoregulation
Article
作者: Yue, Yan ; Wang, Wenqi ; Li, Shuoyuan ; Cheng, Lei ; Zhou, Zongke ; Li, Qiaochu ; Li, Jiyao ; Chen, Xiaoting ; Han, Mingyue ; Yang, Jiaojiao ; Zhang, Yangming ; Li, Jianshu ; Wang, Duan ; Cao, Jian ; Wan, Xufeng
Abstract:
Implant‐associated infections (IAIs) are the main cause of prosthetic implant failure. Bacterial biofilms prevent antibiotic penetration, and the unique metabolic conditions in hypoxic biofilm microenvironment may limit the efficacy of conventional antibiotic treatment. Escaping survival bacteria may not be continually eradicated, resulting in the recurrence of IAIs. Herein, a sonosensitive metal‐organic framework of Cu‐TCPP (tetrakis(4‐carboxyphenyl) porphyrin) nanosheets and tinidazole doped probiotic‐derived membrane vesicles (OMVs) with high‐penetration sonodynamic therapy (SDT), bacterial metabolic state interference, and bacterial cuproptosis‐like death to eradicate IAIs is proposed. The Cu‐TCPP can convert O2 to toxic 1O2 through SDT in the normoxic conditions, enhancing the hypoxic microenvironment and activating the antibacterial activity of tinidazole. The released Cu(II) under ultrasound can be converted to Cu(I) by exogenous poly(tannic acid) (pTA) and endogenous glutathione. The disruption of the bacterial membrane by SDT can enhance the Cu(I) transporter activity. Transcriptomics indicate that the SDT‐enhanced Cu(I) overload and hypoxia‐activated therapy hinder the tricarboxylic acid cycle (TCA), leading to bacterial cuproptosis‐like death. Moreover, the OMVs‐activated therapy can polarize macrophages to a M2‐like phenotype and facilitate bone repair. The sonodynamic biofilm microenvironment modulation strategy, whereby the hypoxia‐enhanced microenvironment is potentiated to synergize SDT with OMVs‐activated therapy, provides an effective strategy for antibacterial and osteogenesis performance.
2024-10-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
3D printed tinidazole tablets coupled with melt-extrusion techniques for formulating child friendly medicines
Article
作者: Banerjee, Subham ; Pawar, Abhishek ; Karanwad, Tukaram
This study investigates the feasibility of fabrication of poly(1-vinyl-2-pyrrolidone) (Kollidon®25)-mediated filaments for producing tinidazole (TNZ)-loaded, customizable, child-friendly tablets (with varying shapes and sizes) using hot melt extrusion (HME) coupled with fused deposition modeling (FDM) technology. Kollidon®25, chosen for its ability to enhance the dissolution of TNZ (a BCS Class II drug), was evaluated for polymer-drug compatibility through Hansen solubility, polarity, and interaction parameter analyses, confirming good miscibility and affinity between TNZ and Kollidon®25. Placebo- and TNZ-loaded filaments were prepared in different ratios using HME, followed by the development of 3D-printed tablets via FDM. The fabricated batches of placebo and TNZ-loaded 3D tablets were characterized, and it was found that they had an average weight variation of 270.41 ± 7.44 mg and 270.87 ± 9.33 mg, hardness of 155.01 ± 11.79 N and 265.3 ± 7.62 N, and friability of 0.1583 ± 0.0011 % and 0.2254 ± 0.0013 %. Amorphization was confirmed by differential scanning calorimetry (DSC) and powder X-ray diffraction (PXRD) analysis. Scanning electron microscopy (SEM) revealed a layer-by-layer pattern with tiny fractures on the tablet surfaces, which enhanced media penetration, resulting in improved dissolution profiles. The TNZ release profile showed complete 100 % release within 2.0 h in a gastric acidic medium. These findings support the potential of Kollidon®25 to create customizable, child-friendly, 3D-printed dosage forms with different shapes and sizes for TNZ delivery, offering a unique approach to paediatric medications.
100 项与 替硝唑 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细菌性阴道炎 | 美国 | 2007-05-21 | |
| 阿米巴病 | 美国 | 2004-05-17 | |
| 贾第虫病 | 美国 | 2004-05-17 | |
| 滴虫感染 | 美国 | 2004-05-17 | |
| 细菌感染 | 中国 | 1994-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 593 | (Tinidazole 1 gm) | 憲構構鹹淵範積醖遞積(鹹憲廠製鹹範鹽糧遞製) = 憲顧壓範選鏇膚構淵選 齋鹽憲獵廠築淵壓餘壓 (糧鹽憲憲鬱齋觸鑰鑰網, 積艱醖鏇網鏇選鑰網憲 ~ 鬱繭網夢積餘淵齋網鹽) 更多 | - | 2011-06-23 | ||
(Control) | 鏇選遞醖鑰蓋築糧壓願(觸繭膚簾繭夢鏇淵鹽鏇) = 積積範廠觸壓製顧遞襯 遞淵襯憲選廠鬱衊壓鑰 (獵鏇網願顧艱選壓淵願, 壓膚鑰艱築製蓋淵築選 ~ 築鹽醖範衊餘鏇糧蓋齋) | ||||||
临床3期 | 235 | 淵壓選襯築襯網襯夢糧(淵齋鏇築積淵齋網壓繭) = 齋鹹餘簾獵網衊憲廠積 壓範鏇繭膚齋餘網製簾 (鏇範憲鹽鑰蓋蓋廠觸蓋 ) | - | 2007-08-01 | |||
淵壓選襯築襯網襯夢糧(淵齋鏇築積淵齋網壓繭) = 鏇艱壓鹹築遞夢獵壓壓 壓範鏇繭膚齋餘網製簾 (鏇範憲鹽鑰蓋蓋廠觸蓋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用